Inhaled Iloprost for Severe Pulmonary Hypertension
Ингаляционный илопрост при тяжелой легочной гипертензии
2002-08-01
SCID: 54.1/343975rb
Discuss with AI
NYHA functional classchronic thromboembolic pulmonary hypertensioninhaled iloprostpulmonary arterial hypertensionsix-minute walk distance
Figures from the paper
Abstract (AI)
BACKGROUND: Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension. METHODS: We compared repeated daily inhalations of 2.5 or 5.0 microg of iloprost (six or nine times per day; median inhaled dose, 30 microg per day) with inhalation of placebo. A total of 203 patients with selected forms of severe pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (New York Heart Association [NYHA] functional class III or IV) were included. The primary end point was met if, after week 12, the NYHA class and distance walked in six minutes were improved by at least one class and at least 10 percent, respectively, in the absence of clinical deterioration according to predefined criteria and death. RESULTS: The combined clinical end point was met by 16.8 percent of the patients receiving iloprost, as compared with 4.9 percent of the patients receiving placebo (P=0.007). There were increases in the distance walked in six minutes of 36.4 m in the iloprost group as a whole (P=0.004) and of 58.8 m in the subgroup of patients with primary pulmonary hypertension. Overall, 4.0 percent of patients in the iloprost group (including one who died) and 13.7 percent of those in the placebo group (including four who died) did not complete the study (P=0.024); the most common reason for withdrawal was clinical deterioration. As compared with base-line values, hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation (P<0.001), were largely unchanged when measured before iloprost inhalation, and were significantly worse in the placebo group. Further significant beneficial effects of iloprost treatment included an improvement in the NYHA class (P=0.03), dyspnea (P=0.015), and quality of life (P=0.026). Syncope occurred with similar frequency in the two groups but was more frequently rated as serious in the iloprost group, although this adverse effect was not associated with clinical deterioration. CONCLUSIONS: Inhaled iloprost is an effective therapy for patients with severe pulmonary hypertension.
Key Findings
1
Hemodynamic measurements improved significantly after iloprost inhalation, while pre-inhalation values were largely unchanged and placebo-group hemodynamics worsened.
2
Iloprost also improved NYHA functional class, dyspnea, and quality of life, with syncope occurring at similar frequencies in both groups.
3
Iloprost increased six-minute walking distance by 36.4 m overall and by 58.8 m among patients with primary pulmonary hypertension.
4
Inhaled iloprost significantly increased the proportion of patients meeting the combined clinical endpoint versus placebo: 16.8% versus 4.9% (P=0.007).
5
Study withdrawal was less frequent with iloprost than placebo, largely because fewer patients experienced clinical deterioration: 4.0% versus 13.7% (P=0.024).
Research Object
Patients with severe pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (NYHA functional class III or IV)
Research Subject
The efficacy and safety of repeated inhaled iloprost, including effects on pulmonary hemodynamics, exercise capacity, functional class, symptoms, quality of life, and clinical deterioration
Publication Details
Publication Date
2002-08-01
Journal
Publisher
ISSN
Cited by
1786
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by10
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2015
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2015
Pediatric Pulmonary Hypertension2015
Risk stratification and medical therapy of pulmonary arterial hypertension2018
Pulmonary Arterial Hypertension: Pathophysiology and Treatment2018
Pulmonary Hypertension2017
Prostacyclin for pulmonary arterial hypertension2019
Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis2022
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension2022